The First Four Years:
A compelling growth story. A strong investment. A rapidly advancing pipeline.
Our Four Year Performance
Since our inception as AbbVie, we have built an industry-leading performer with a portfolio and pipeline of innovative medicines that raise the standard of care for serious diseases. We invite you to take a closer look at our performance over the past four years. For a complete look at our 2016 performance, our earnings press release is located here.
Robust and Productive Pipeline
We are committed to discovering new medicines that improve the standard of care for many serious diseases and have a strong late-stage pipeline across several therapeutic areas.
AbbVie has built a leading pipeline of late-stage investigational compounds to treat several serious diseases and conditions. In total, we have more than 50 investigational programs in clinical development.
Strong Return on Capital
AbbVie’s revenue and earnings have grown each year since inception, enabling the company to raise its dividend by 60% and achieve a total return of 111.4%.*
Emerging Strength in Oncology
AbbVie is committed to improving the lives of people affected by cancer and is developing a pipeline of investigational medicines that span 20 different types of solid tumors and blood cancers.
For Investor and Media Use Only - Not For Promotional Use